• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

CEO of Intrabio calls their drug "Splenda packets" lol

anonymous

Guest
The CEO of Intrabio is exactly thrilled about working for that company. He considers it beneath his former grandeur of the position he held as an EVP with Gilead Sciences. He has referred to the founder of Intrabio, Mallory Factor, as a bombastic idiot who embarasses himself when he spastically espouses the virtues of their developmental Neimann Pick drug. The CEO told me he wished Mallory would shut his stupid mouth and let him do the talking when they are communicating with the FDA, investors, and so forth. He's also claimed that Mallory oogles younger, attractive women at private clubs, which would probably be news to his wife, Elizabeth, who is the Chief Administrator of Intrabio. The CEO hasn't been critical of Elizabeth, although he has joked about the name of one of their children, Memorable Factor.

On the topic of Intrabio's one and only drug under development for Neimann Pick, the CEO has criticized it as looking like a packet of Splenda. He said it didn't seem like a serious drug since it could be mistaken for a Crystal Light drink mix. No doubt, after that amazing powder form drug is approved, the CEO will price it like a packet of gold since he is one of the architect's of Gilead's $1,000 per day Hep C drug. His winning formula for pharma success if to price drug's very high, at least, until they have some competition. Neimann Pick victims (or their insurance companies) better buckle up to swallow that expensive pill (or packet or whatever).